Density-dependent decay in HIV-1 dynamics

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 3, 2006, Pages 266-276

  Holte, Sarah E ^a   Melvin, Ann J ^b   Mullins, James I ^c   Tobin, Nicole H ^b   Frenkel, Lisa M ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Combination therapy; Infected cell decay; Mathematic models; Models projections; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ANIMAL CELL; ARTICLE; CELL COMPARTMENTALIZATION; CELL POPULATION; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGLINEAR MODEL; MATHEMATICAL MODEL; NONHUMAN; POPULATION DENSITY DEPENDENCE; PRIORITY JOURNAL; TIME SERIES ANALYSIS; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RNA, VIRAL; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 33645097339     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000199233.69457.e4     Document Type: Article

References (73)

1. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
2. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics of HIV-1 infection. Nature. 1995;373:117-122.
3. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
4. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature. 1997;387:188-191.
5. Notermans DW, Gudsmit J, Danner SA, et al. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS. 1998;12:1483-1490.
6. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on re-initiated treatment. AIDS. 1999;13:677-683.
7. Wu H, Kuritzkes DR, McClernon DR, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologie end points. J Infect Dis. 1999;179:799-807.
8. Luzuriaga K, Wu H, McManus M, et al. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol. 1999;73:362-367.
9. Melvin AJ, Rodrigo AG, Mohan KM, et al. HIV-1 dynamics in children. J Acquir Immune Defic Syndr. 1999;20:468-473.
10. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605-1613.
11. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82-85.
12. Havlier DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171-179.
13. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy. JAMA. 2001;286:197-207.
14. Cohen Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28:105-113.
15. Greub GA, Cozzi-Lepri B, Ledergerber S, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967-1969.
16. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817-829.
17. Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol. 2005;79:1.
18. Davey RT, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA. 1999;96:15109-15114.
19. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS. 1999;13(Suppl):F79-F86.
20. Furtado MR, Duncan S, Callaway S, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-1622.
21. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci USA. 1999;96:10958-10961.
22. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
23. Hoppensteadt FC. Mathematical Methods of Population Biology. New York: Cambridge University Press; 1982.
24. + T cell pools. Eur J Immunol. 1995;25:2127-2136.
25. + T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol. 1999;17:625-656.
26. Hockett RD, Kibly JM, Derdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med. 1999;189:1545-1554.
27. Arnaout RA, Nowak MA, Wodarz D. HIV-1 dynamics revisited: biphasic decay or cytotoxic T lymphocyte killing? Proc R Soc Lond B Biol Sci. 2000;267:1347-1354.
28. Muller V, Vigueras-Gomez JF, Bonhoeffer S. Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection. J Virol. 2002;76:8963-8965.
29. Wu H, Huang Y, Acosta EP, et al. Modeling long-term HIV dynamics and antiretroviral response. J Acquir Immune Defic Syndr. 2005;39:272-283.
30. Boom R, Sol CJ, Salimans MM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990;28:495-503.
31. Brambilla DJ, Granger S, Jennings C, et al. Multisite comparison of reproducibility and recovery from the standard and ultra sensitive Roche AMPLICOR HIV-1 MONITOR assays. J Clin Microbiol. 2001;39:1121-1123.
32. Mulder J, Resnick R, Saget B, et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol. 1997;35:1278-1280.
33. HYPERMUT [computer program]. Los Alamos: Los Alamos National Laboratory; 1999.
34. Rose PP, Korber BT. Detecting hypermutations in viral sequences with an emphasis on G to A hypermutation. Bioinformatics. 2000;16:400-401.
35. Vartanian JP, Meyerhans A, Asjo B, et al. Selection, recombination, and G to A hypermutation of human immunodeficiency virus type 1 genome. J Virol. 1991;65:1779-1788.
36. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting position-specific gap penalties and weight matrix choice. Nucleic Adds Res. 1994;22:4673-4680.
37. Swofford DL. PAUP* 4.0: Phylogenetic Analysis Using Parsimony (*and other methods) [computer program]. 4.0b2a ed. Sunderland: Sinauer Associates; 1999.
38. Akaike H. A new look at statistical model identification. Autom Contr. 1974;19:716-723.
39. Posada D, Crandall KA. MODELTEST: testing the model of DNA substitution. Bioinformatics. 1998;14:817-818.
40. + monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol. 2002;76:707-716.
41. Hlavecek WS, Stilianakis NI, Wotermans DA, et al. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc Natl Acad Sci USA. 2000;97:10966-10971.
42. Louie M, Hogan C, Di Mascio M, et al. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis. 2003;187:896.
43. Efron B, Tibshirani RJ. An Introduction to the Boostrap. New York: Chapman Hall; 1993.
44. Venzon DJ, Moolgavkar SH. A method for computing profile-likelihood-based confidence intervals. Appl Stat. 1988;37:87-94.
45. Barone MA, ed. In: The Harriet Lane Handbook: A Manual for Pediatric House Officers. 14th ed. St. Louis: Mosby-Year Book; 1996.
46. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-188.
47. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94:13193-13197.
48. + T cells. Proc Natl Acad Sci USA. 1997;94:9332-9336.
49. Derdeyn CA, Kilby JM, Miralles GD, et al. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type-1-infected subjects in the absence or presence of effective therapy. J Infect Dis. 1999;180:1851-1862.
50. Palumbo PE, Kwok S, Waters S, et al. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr. 1995;126:592-595.
51. Tetali S, Abrams E, Bakshi S, et al. Virus load as a marker of disease progression in HIV-infected children. AIDS Res Hum Retroviruses. 1996;12:669-675.
52. Chun TW, Davey RT, Engel D, et al. Re-emergence of HIV after stopping therapy. Nature. 1999;401:874-875.
53. Bucy RP. Immune clearance of HIV type 1 replication-active cells: a model of two patterns of steady state HIV infection. AIDS Res Hum Retroviruses. 1999;15:223-227.
54. + T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI. J Virol. 1997;71:4436-4444.
55. Pal A, Greenough TC, Sullivan J, et al. In vitro characterization of adult primary human immunodeficiency virus type 1; demonstration of distinctive single-cell killing phenotypes in spite of similar levels of viral replication. J Infect Dis. 1997;176:933-940.
56. Anderson RW, Ascher MS, Sheppard HW. Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: a worst-case dynamic analysis. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:245-252.
57. + T lymphocytes in HIV-1-infected PHA-stimulated PBL cultures is mediated by CD8+ LAK cells. J Virol. 1998;241:169-180.
58. Finkel T, Tudor-Williams G, Banda M, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cell of HIV- and SIV-infected lymph nodes. Nat Med. 1995;1:129-134.
59. Ogg GS, Jin X, Bonhoeffer S, et al. Quantification of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103-2106.
60. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol. 1999;73:797-800.
61. Dalod M, Dupuis M, Deschemin JC, et al. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8+ responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol. 1999;73:7108-7116.
62. Gray CM, Lawrence J, Schapiro JM, et al. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol. 1999;162:1780-1788.
63. Kalams SA, Goulder PJ, Shea AK, et al. Levels of human fsimmunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol. 1999;73:6721-6728.
64. Speigel HM, DeFalcon E, Ogg GS, et al. Changes in frequency of HIV-1 specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J Infect Dis. 1999;180:359-368.
65. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ lymphocytes. Proc Natl Acad Sci USA. 2000;97:3382-3387.
66. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 1999;5:518-525.
67. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103-6110.
68. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283:857-860.
69. + T cells during primary HIV-1 infection. Proc Natl Acad Sci USA. 1998;95:8869-8873.
70. Nowak MA, Bangham CR. Population dynamics of immune responses to persistent viruses. Science. 1996;272:74-79.
71. Strain MC, Gunthard HF, Havlir DV, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA. 2003;100:4819-4824.
72. + T cells in acute human immunodeficiency virus type I infection. J Infect Dis. 2000;182:1636-1642.
73. + T lymphocytes in infected children. J Clin Invest. 2000;105:995-1003.